
    
      The aim of this study is to determine whether oral Chinese herbal medicine in combination
      with secukinumab is effective and safe in the treatment of severe psoriasis. Eligible
      participants will be treated with oral Chinese herbal medicine and secukinumab concurrently.
      No controlled group will be set up in this trial. The primary outcome is time to relapse.
      Secondary outcomes include Psoriasis Area and Severity Index (PASI) 75/90, PASI score
      reduction rate, physician's global assessment (PGA) score, body surface area (BSA) score,
      visual analogue scale (VAS) score, dermatology life quality index (QLQI) and Skindex 16.
    
  